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Abstract
While it is well known that the presence of lymphocytes and cytokines are important for fracture healing, the exact role of
the various cytokines expressed by cells of the immune system on osteoblast biology remains unclear. To study the role of
inflammatory cytokines in fracture repair, we studied tibial bone healing in wild-type and Rag1
2/2 mice. Histological
analysis, mCT stereology, biomechanical testing, calcein staining and quantitative RNA gene expression studies were
performed on healing tibial fractures. These data provide support for Rag1
2/2 mice as a model of impaired fracture healing
compared to wild-type. Moreover, the pro-inflammatory cytokine, IL-17F, was found to be a key mediator in the cellular
response of the immune system in osteogenesis. In vitro studies showed that IL-17F alone stimulated osteoblast maturation.
We propose a model in which the Th17 subset of T-lymphocytes produces IL-17F to stimulate bone healing. This is a pivotal
link in advancing our current understanding of the molecular and cellular basis of fracture healing, which in turn may aid in
optimizing fracture management and in the treatment of impaired bone healing.
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Introduction
The molecular and cellular regulation of fracture healing is not
completely understood, yet such knowledge is critical to develop-
ing treatments to optimize bone repair and remodeling. There is
growing evidence that inflammation plays a crucial role in early
fracture repair [1–5]. In mouse models, interleukin (IL) 21, 26
and tumor necrosis factor a (TNFa) expression is present in the
fracture site within the first 24 h period post-injury with both
TNFa and IL-6 knockout mice demonstrating delayed endochon-
dral repair and callus remodeling [3,6]. Similar to other injury
states, such as wound healing [7], the immunologic response is
pivotal in initiating the necessary triggers that result in cellular
differentiation required for successful bone healing. Although most
osteoimmunology research has centered on the areas of inflam-
matory and metabolic bone processes [8], in diseases such as
rheumatoid arthritis and osteoporosis, interest within the context
of other pathological conditions, such as fracture healing, has been
a more recent focus. The molecular links between bone and the
immune system have emerged from the identification of receptor
activator of nuclear factor-kappaB/ligand (RANK) and RANKL
as key osteoclastogenic molecules. However, immunological
regulation of the osteoblast has been a particularly poorly
understood topic to date. While it is well known that there exists
a mutual interaction between osteoblast and osteoclast cells
through RANK-RANKL signaling [8–12], the role of lympho-
cytes and cytokines in osteoblast biology with respect to osteoblast
activation and maturation during fracture healing remains
unknown [13–15].
In normal fracture healing, osteoblasts synthesize osteoid
matrix which is eventually mineralized to produce bone. Cells
of the osteoblast lineage include bone-lining cells and osteocytes,
the latter of which becomes embedded in the lacunae as the
surrounding bone is formed. Runt-related transcription factor 2/
core binding factor 1 (Runx2) and Osterix (OSx) are both known
transcription factors essential for early osteoblast differentiation.
Similarly, activation of the canonical Wnt and bone morpho-
genic protein (BMP) signaling pathways are known to play a role
in osteoblast differentiation [16]. Yet exactly how these pathways
are affected by the immune system remains an ongoing area of
investigation.
Mice lacking recombinase activating genes Rag1 or Rag2 are
unable to form T-cell or B-cell receptors and hence, completely
lack mature T and B lymphocytes [17,18]. The Rag1 and Rag2
proteins act in combination as a heterodimer to facilitate the
rearrangement of variable (V), diversity (D) and joining (J) genes
required for the generation of immunoglobulin and T-cell
receptors. This rearrangement is necessary for diversity in antigen
recognition and is permissive in allowing the developing B-cells
and T-cells to mature and enter the circulation. In turn, Rag1
deficient mice are devoid of any lymphocytic sources of
interleukins and provide a preclinical model of fracture healing
in the absence of these secreted factors. Thus, the Rag1
2/2 mouse
PLoS ONE | www.plosone.org 1 June 2012 | Volume 7 | Issue 6 | e40044is a useful animal to elucidate the physiological role of T-cells and
their subtypes on osteoblast differentiation during fracture healing.
Materials and Methods
Ethics Statement
All studies followed the Canadian Council of Animal Care
(CCAC) guidelines and all procedures were approved by
Sunnybrook Health Sciences Centre Animal Care Committee.
(AUP#09-407). All surgery was performed under isoflurane gas
anesthesia, and all efforts were made to minimize suffering.
Mice
B6.129S7-Rag1
tm1Mom/J (Rag1
2/2) and C7BL/6J wildtype (WT)
male 12-week old mice were used (Jackson Laboratory, Bar
Harbor, Maine). A longitudinal incision was made over the knee,
and a 0.5 mm hole was made just proximal to the tibial tubercle
and lateral to the patellar tendon. The tibia was pre-stabilized by
placing an 0.9 mm intramedullary pin (Fine Science Tools,
http://www.finescience.com/) in the marrow space as previously
reported [19] with the following modifications. The fracture was
generated by an open osteotomy in the mid shaft of the tibia
through a separate small anterolateral incision with minimal soft
tissue dissection. Previous data show that a fracture generated in
this manner heals through both endochondral and intramembra-
nous ossification [20]. It allows for consistency in fracture
generation with respect to fracture level, orientation (ie. transverse
vs. multi-fragmentary) and controlling for the fibula to remain
intact, thus minimizing for variability between specimens and
allowing a more homogeneous assessment of fracture callus cell
types. The animals were allowed unrestricted weight-bearing
immediately following surgery. Mice were euthanized at different
time points post fracture and the limbs were harvested for analysis.
Cytokine/Chemokine Measurements
The serums of WT and Rag1
2/2 mice were drawn at 2 days
post-fracture for detection and quantification of immunologic
proteins in the early phase of repair. The levels of 32 cytokines/
chemokines (Eotaxin, G-CSF, GM-CSF, IFN-c, IL-1a, IL-1b, IL-
2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-9, IL-10, IL-12 (p40), IL-12
(p70), IL-13, IL-15, IL-17, IP-10, KC, LIF, LIX, MCP-1, M-CSF,
MIG, MIP-1a, MIP-1b, MIP-2, RANTES, TNFa, VEGF) were
assessed with the Mouse Cytokine/Chemokine MilliplexTM Map
kit (Millipore, Billerica, MA) using LuminexH technology accord-
ing to the manufacturer’s instructions and assayed with the
Luminex100ISTM system by Linco Research, Inc. The cytokine
detection limit for this assay was 3.2 pg/mL.
In vitro Studies
To determine whether the presence or absence of mature T-cells
influence osteoblast differentiation, primary mesenchymal stromal
cells (MSC) were harvested from bilateral femurs, tibias and humeri
of 12 week old WT and Rag1
2/2 mice. After lysis of red blood cells
usingACKlysisbuffer,5.0610
6/mLcellswereseededper12multi-
well plate for 7 days in a 37uC incubator (Becton Dickinson) in
aMEM (Wisent, St-Bruno, Quebec) containing high glucose
supplemented with 100 U/ml penicillin, 100 mg/ml streptomycin,
and10%fetalcalfserum.Atday4,halfofthemediacontainingnon-
adherent cells was exchanged with fresh media and at day 7, the
media was changed completely to osteoblast differentiation media
(aMEM supplemented with 50 mg/ml ascorbic acid (Sigma-
Aldrich, St. Louis, MO), 10
28 M dexamethasone (Sigma-Aldrich,
St. Louis, MO), and 8 mM b-glycerophosphate (Sigma-Aldrich, St.
Louis,MO).Cellswereharvestedat20daysforRNAextractionand
analysis with RNeasyH Plus Mini Kit (Qiagen, Valencia, CA) for
quantitative real-time RT-PCR and staining with Alizarin red.
Murine pre-osteoblast cell line, MC3T3-E1, were maintained in
aMEM supplemented with 2.5% fetal bovine serum (FBS; Gibco,
Invitrogen) and 100 U/ml penicillin and 100 mg/ml streptomycin
37uCi n5 %C O 2 atmosphere. The spontaneous differentiation
into osteoblasts of MC3T3-E1 and primary mesenchymal stromal
cells was induced by osteoblast differentiation media as above. For
IL-17F treatment, 2.5610
5 MC3T3-E1 cells and 2.5610
5 primary
mesenchymal stromal cells as prepared above were seeded in 6-
well plates with aMEM added with 20 ng/ml of IL17F (R&D
Table 1. List of Primers.
No. Gene Sequence (59 to 399)
1 GAPDH Forward AACTTTGGCATTGTGGAAGG
Reverse ACACATTGGGGGTAGGAACA
2 IFNc Forward ACTGGCAAAAGGATGGTGAC
Reverse TGAGCTCATTGAATGCTTGG
3T N F a Forward AGCCCCCAGTCTGTATCCTT
Reverse CTCCCTTTGCAGAACTCAGG
4T G F b Forward TTGCTTCAGCTCCACAGAGA
Reverse TGGTTGTAGAGGGCAAGGAC
5 IL-1 Forward CCCGTCCTTAAAGCTGTCTG
Reverse AATTGGAATCCAGGGGAAAC
6 IL-4 Forward TCAACCCCCAGCTAGTTGTC
Reverse TGTTCTTCGTTGCTGTGAGG
7 IL-6 Forward AGTTGCCTTCTTGGGACTGA
Reverse TCCACGATTTCCCAGAGAAC
8 IL-10 Forward CCAAGCCTTATCGGAAATGA
Reverse TTTTCACAGGGGAGAAATCG
9 IL-12b Forward AGGTGCGTTCCTCGTAGAGA
Reverse AAAGCCAACCAAGCAGAAGA
10 IL-13 Forward CAGCTCCCTGGTTCTCTCAC
Reverse CCACACTCCATACCATGCTG
11 IL-17A Forward TCCAGAAGGCCCTCAGACTA
Reverse AGCATCTTCTCGACCCTGAA
12 IL-17F Forward GTGTTCCCAATGCCTCACTT
Reverse GTGCTTCTTCCTTGCCAGTC
13 IL-23 Forward GACTCAGCCAACTCCTCCAG
Reverse GGCACTAAGGGCTCAGTCAG
14 ALP Forward CCAGCAGGTTTCTCTCTTGG
Reverse CTGGGAGTCTCATCCTGAGC
15 Col1 Forward GAGCGGAGAGTACTGGATCG
Reverse GCTTCTTTTCCTTGGGGTTC
16 Col2 Forward GCCAAGACCTGAAACTCTGC
Reverse GCCATAGCTGAAGTGGAAGC
17 BSP2 Forward AAAGTGAAGGAAAGCGACGA
Reverse GTTCCTTCTGCACCTGCTTC
18 Runx2 Forward CCCAGCCACCTTTACCTACA
Reverse TATGGAGTGCTGCTGGTCTG
19 Osteocalcin Forward CTTGGTGCACACCTAGCAGA
Reverse ACCTTATTGCCCTCCTGCTT
doi:10.1371/journal.pone.0040044.t001
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treatment, 10 ng/ml (R&D systems, Minneapolis, MN) was used.
Cells were harvested and RNA was extracted for analysis with
osteoblast and cytokine markers (Table 1).
Fracture Analysis
Tibias were harvested at 3, 7, 14, 21, 28 and 35 days post-
fracture. Tibias harvested at 3 and 7 days were fixed in 4%
paraformaldehyde for histological analysis, decalcified in 10%
EDTA (pH 7.4) for 3 weeks, dehydrated and embedded in
paraffin. Sections 10 mm thick were prepared with Safranin O
staining (Sigma) (n=3) for histologic analysis. Immunohistochem-
istry (IHC) was performed using ABC Kit (Vector Laboratories,
Burlingame, CA) following the standard manufacturer protocol.
The monoclonal anti-CD3 with goat anti-rabbit and anti-mouse
immunoglobulin (Ig) from Abcam (Cambridge, CA) was used. The
anti-mouse IL-17F antibody from R&D Systems (Minneapolis,
MN) was used. Tibias harvested at 3 and 7 days also underwent
total RNA isolation from their callus. The callus was snap frozen
in liquid nitrogen, processed by BioPulvenizer (MidSci) and total
RNA was extracted using TRIZOL (Invitrogen). Quantitative
real-time reverse transcriptase polymerase chain reaction (RT-
PCR) was performed with StepOnePlus system (Applied Biosys-
tems) using SYBR Green (Bio-Rad). The primers are listed in
Table 1.
Fractured and unfractured tibias harvested at 14, 21 and 28
days for both WT and Rag1
2/2 mice were fluorochrome labeled
with calcein green as described by van Gaalen et al, 2010 [21]
(n=3 per group). At 2 and 9 days prior to harvest, mice were given
30 mg/kg calcein green (Sigma-Aldrich, St. Louis, MO) via
peritoneal injections to sequentially label new bone deposition and
bone remodeling during a one week healing period. Briefly,
harvested tibias were fixed in 70% ethanol. In vacuum jars,
specimens were sequentially dehydrated using ascending acetone
concentrations. Following dehydration, the infiltration process was
performed with increasing concentrations of Spurr resin (50, 80,
26100%) (SPI-Pon
TM 812 Embedding Resin System). Sections of
7 mm were cut in the long axis of the tibia using a rotary
microtome (Leica RM 2165) for fluorescent microscopy imaging
(495 nm/521 nm, FITC) and analysis (Bioquant, Nashville, TN).
Micro-computed Tomography Analysis
WT and Rag1
2/2 mice tibias harvested at 28 and 35 days were
used for micro-computed tomography (mCT) based stereologic
analysis and standard torsional biomechanical testing. Character-
ization of callus geometry and mineralization was analyzed using
high resolution mCT. Samples were scanned at an isotropic voxel
size of 8 mm (SkyScan 1172, SkyScan, Belgium) using a voltage of
50 kV, a current of 160 mA, and a 0.5 mm aluminum filter.
Samples were placed with the long axis of the tibia coincident with
the vertical axis of the scanner, and scanned in combination with
calibrated bone density phantoms to allow direct measurements of
bone density from the scans using a linear relationship.
Three-dimensional callus properties of geometry and mineral-
ization were calculated using the custom processing option
available in CTAn software (SkyScan, Belgium) and in-house
code in AmiraDEV (VGS, Germany). Structural and material
parameters were calculated by first segmenting the images with a
global threshold value of 0.2 gHA/cm
3 to define voxels corre-
sponding to bone [22]. Following a despeckling filter to remove
noise in the images, a region of interest (ROI) was fitted around
the callus on subsequent axial slices using an adaptive contouring
algorithm which ignored holes in the outside of the callus of less
than 50 pixels. Measurements of the callus properties in the ROI
included Bone Volume (BV, mm
3), Total Callus Volume (TV,
mm
3), Bone Volume Fraction (BV/TV, %), Trabecular Thickness
(Tb.Th., mm), Trabecular Number (Tb.N., 1/mm), Trabecular
Separation (Tb.Sp., mm), Mean Bone Mineral Density (BMD,
gHA/cm
3), Mean Tissue Mineral Density (TMD, gHA/cm
3) and
Torsional Rigidity (CTRA, kNmm
2) [23].
Mechanical Testing
Torsional strength and torsional stiffness were measured at 28
and 35 days using a MTS Bionix 858 (MTS Systems, MN, USA)
materials testing system. Prior to testing, intramedullary pins and
fibulas were removed from all tibias using sharp bone scissors.
Each tibia was then aligned longitudinally to the loading axis of
the MTS and potted proximal and distal to the fracture callus in
polymethylmethacrylate. The gauge length, defined as the length
between the two potting casings, was kept consistent for each
sample. Torque was measured during the application of angular
displacement (1u/second) until failure or to a maximum displace-
ment of 30u. The maximum torque, twist angle at failure, and
torsional stiffness were calculated based on the generated load
displacement data. Torsional strength was defined as the
maximum load sustained during loading, and the torsional
stiffness was defined as the slope of the line extending to the
point of maximum sustained torque.
Statistical Analysis
Data were expressed as mean 6 standard deviation. Statistical
differences were calculated using a Student t test. Unless stated
otherwise, 10 animals were utilized per group for the RT-PCR
expression data; 9 animals (WT) and 8 animals (Rag1
2/2) were
used for mCT stereology and biomechanical analyses. A p value
below 0.05 was considered statistically significant.
Results
T-cells are Present in the Early Phase of Fracture Repair
and Correlates to Bone Marker Gene Expression
To confirm the role of T-cells as an early responder in the
fracture healing cascade, immunohistochemistry of WT mice
fracture callus was analyzed. CD3, a marker ubiquitously
expressed in T-cells, was used to identify these cells in the fracture
region. A low magnification Safranin O section (Fig. 1A) was used
to illustrate the region of interest whereby higher magnification
images corroborated the histology (Fig. 1B) and positive CD3
staining of T-cells which characteristically localized adjacent to the
endosteum in the fracture hematoma at 3 days post fracture in all
sections (Fig. 1C). The Rag1
2/2 mice at 3 days post fracture did
not show any specific T-cell staining in multiple high power field
regions in the fracture callus (Fig. 1D). The distribution of T-cells
predominantly in the endosteal fracture hematoma was represen-
tative in the all the WT mice CD3 immunohistochemistry during
this early phase of healing. Following the inflammatory phase at 7
days post fracture, immunostaining results showed a reduction in
the presence of T-cells at the fracture site in similar sections during
the later stages of bone healing (data not shown). Although the
presence of B-cells in the fracture hematoma has been observed
[12], antigen processing and clonal expansion is not a known early
response of fracture healing. While CD45R antibody staining is
commonly used as a marker of B-cells, there are reported
examples of cross-reactivity in the mouse with positive immuno-
fluorescence and signal transduction of T-cells using CD45R [24]
and therefore, any positive CD45R staining would be equivocal in
concluding B-cell specificity.
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phases of fracture healing (7, 14, 28 days post fracture) showed no
significant differences in mature bone marker expression between
WT and Rag1
2/2 mice (data not shown), the presence of T-cells at
3 days post fracture correlated with the level of expression of
mature bone markers, detected using real-time quantitative RT-
PCR normalized to GAPDH. Expression of Collagen 1 (Col1)
(p,0.01), Collagen 2 (Col2) (p,0.05), bone sialoprotein (BSP)
(p,0.01), BMP2 (p,0.01) and Runx2 (p,0.05) were significantly
increased in WT compared to Rag1
2/2 mice at 3 days post
fracture (Fig. 1E). The Rag1
2/2 mice which lack mature T-cells
generally showed a failure to increase bone marker expression 3
days post fracture. Both Col1 and BSP were more significantly
decreased at a p value ,0.01. BSP has the biophysical and chemical
properties of a nucleator and its temporo-spatial expression has
shown to coincide with de novo mineralization in bone [25]. The
significant decrease in BSP suggests an impairment in Rag1
2/2
mice in its ability to up-regulate BSP in osteoblasts to form bone.
Pro-inflammatory Cytokine Expression is Decreased and
Anti-inflammatory Cytokine Expression is Increased in
the Fracture Callus of Rag1
2/2 Mice
To gain further insight as to the relevant cytokines involved
during early T-cell activation and osteoblast maturation, thirty-
two cytokines and chemokines were profiled and their expression
analyzed using a protein assay of mice serum 2 days post fracture.
Cytokines IL-6 and granulocyte colony-stimulating factor (G-CSF)
were significantly lower in Rag1
2/2 mice compared to WT mice
(p,0.05) (Fig. 2A). As well, eotaxin (p,0.05), IL-12 (p40) (p,0.05)
and CXC motif chemokine 10 (IP-10) (p,0.05) were elevated in
Rag1
2/2 mice compared to WT whereas CXC chemokine ligand
5 (LIX) (p,0.01) and CXC motif ligand 9 (MIG) (p,0.01) were
decreased in Rag1
2/2 mice (data not shown). The remainder of
the cytokine/chemokine panel showed no significant difference in
expression between WT and Rag1
2/2 mice at this 2 day time
point (n=3 per group).
The systemic changes in cytokine and chemokine expression
during the early phase of healing were further assessed locally at
the fracture callus. Quantitative RT-PCR of the extracted RNA at
3, 7, 14 and 28 days was screened using several known cytokines
previously identified in fracture healing (Table 1). The regulatory
patterns of the cytokines at 3 days showed a characteristic
grouping. The pro-inflammatory cytokines IL-6 (p,0.05), IL-17F
(p,0.05) and IL-23 (p,0.05) were expressed at significantly lower
levels in the Rag1
2/2 mice compared to WT, while the anti-
inflammatory cytokines IL-10 (p,0.05) and TGFb (p,0.05) were
expressed at much higher levels relative to WT mice (Fig. 2B). Of
note, IL-17A which has an important role in regulating
osteoclastogenesis, was found to be undetectable in WT and
Rag1
2/2 mice at any of the early or late time points studied
indicating that IL-17A is not induced during the fracture repair
process. Immunohistochemistry was completed using an IL-17F
antibody to confirm the presence of a pro-inflammatory cytokine
in the fracture site during the early phase of healing in WT and
Rag1
2/2 mice 3 days post fracture (Fig. 2C). The presence of IL-
17F was noted in the WT mice fracture hematoma similar to the
distribution of the previous CD3 staining of T-cells. Predictably,
the Rag1
2/2 mice showed no appreciable IL-17F staining in this
same region. Unfractured and 7 day post fractured tibias
demonstrated no appreciable positive IL-17F staining (data not
shown). However, the level of TGFb expression in Rag1
2/2 mice
was comparable to baseline, unbroken limbs suggesting a
constitutive activity of TGFb in WT mice that is down-regulated
post fracture. The TGFb down-regulation in Rag1
2/2 mice was
not observed. Similarly, the up-regulation of IL-6 and IL-17F in
Rag1
2/2 mice was also absent. In fact, IL-10 was the only cytokine
up-regulated post fracture in the Rag1
2/2 mice.
At 7, 14 and 28 days, no significant differences were seen
between the Rag1
2/2 and WT mice in their cytokine expression,
except IL-6, which still remained decreased in Rag1
2/2 compared
to WT mice (data not shown). Thus, the observed regulatory
grouping of cytokines present at 3 days was only specific to the
early phase of fracture healing.
Pro-inflammatory Cytokine, IL-17F, Stimulates Bone
Maturation
To examine the effects of these cytokines on the osteoblast
directly, a MC3T3-E1 pre-osteoblastic cell line was cultured and
treated with IL-17F or TGFb. Cells treated with the pro-
inflammatory cytokine, IL-17F (Fig. 3A left) showed significantly
increased expression of mature bone markers Col1 (p,0.05), Col2
(p,0.05), BSP (p,0.05) and osteocalcin (p,0.05) compared to
untreated cells. Alkaline phosphatase (ALP), a surrogate marker of
early osteogenic differentiation and Runx2, an upstream tran-
scription factor for proteins of osteoblast formation showed no
significant increase with IL-17F treatment. Cells treated with
TGFb (Fig. 3A right) exhibited a reciprocal effect with significantly
decreased levels of all bone markers ALP (p,0.01), Col1 (p,0.05,
Col2 (p,0.05), BSP (p,0.05), Runx2 (p,0.05) and osteocalcin
(p,0.05). This confirmed an inhibitory effect on osteoblast
maturation in these pre-osteoblastic cells with TGFb treatment.
To determine the effects of IL-17F and TGFb on Rag1
2/2 and
WT mice, primary mesenchymal stromal cell cultures were
studied. Rag1
2/2 mice mesenchymal stromal cells treated with
IL-17F promoted osteoblast maturation and showed increased
bone marker expression of Col 1, Col2 and Runx2 (Fig. 3B left).
Primary mesenchymal stromal cells from WT mice treated with
TGFb, suppressed osteoblast maturation and showed a significant
decrease in the expression of all the bone markers assessed (Fig. 3B
right).
There is a Reduction in Osteogenesis during Fracture
Repair in Rag1
2/2 Mice
In vitro cultures of primary mesenchymal stromal cells treated
with osteoblast differentiation media were performed on un-
fractured WT and Rag1
2/2 mice to assess for any inherent
differences in mineralization potential. RNA extracted from
Rag1
2/2 mice primary bone cultures (Fig. 4A) demonstrated
decreased expression of mature bone markers Col1 (p,0.01),
Col2 (p,0.005), BSP (p,0.05) and osteocalcin (p,0.01)
Figure 1. T-cell presence and increased bone marker expression are demonstrated in early fracture repair. (A) Although no cartilage or
new bone formation is expected at 3 days post tibial fracture, low magnification (20X) Safranin O staining of WT mice at this time point helps to
illustrate the region of interest (inset). (B) Higher magnification images corroborate the histology in this region and (C) positive CD3 staining of T-cells
localizing to the endosteal fracture hematoma in contiguous sections (200X). Immunohistochemistry analysis confirms presence of T-cell infiltration
(CD3 – black arrows) in WT mice. (D) In a similar region, no positive staining was seen in Rag1
2/2 mice (200X). (E) T-cell presence is shown to correlate
with gene expression of mature bone markers detected on quantitative RT-PCR normalized to GAPDH. Expression of Col1 (p,0.01), Col2 (p,0.05),
BSP (p,0.01), BMP2 (p,0.01) and Runx2 (p,0.05) were increased in WT compared to Rag1
2/2 mice at 3 days post fracture.
doi:10.1371/journal.pone.0040044.g001
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PLoS ONE | www.plosone.org 5 June 2012 | Volume 7 | Issue 6 | e40044Figure 2. Cytokine expression during the early phase of fracture repair. (A) WT and Rag1
2/2 mice serums drawn 2 days post-fracture show
elevated IL-6 and G-CSF levels compared to unfractured baseline mice. However, WT mice were found to have twice the increase in cytokine levels of
IL-6 and G-CSF compared to Rag1
2/2 mice during this early phase of fracture healing (p,0.05). (B) Fracture callus RNA expression analysis of cytokine
levels at a similar early time point post fracture, shows a greater than 2 fold up-regulation of pro-inflammatory cytokines IL-6, IL-17F and IL-23 in WT
mice compared to Rag1
2/2 and baseline mice (p,0.05). Conversely, expression of anti-inflammatory cytokine IL-10 is up-regulated in Rag1
2/2 and
TGFb is down-regulated in WT mice. (C) Immunohistochemistry analysis during the early phase of fracture healing at 3 days post fracture confirmed
IL-17F positive staining (black arrows) in WT mice similar to the distribution of CD3 staining shown previously with no positive IL-17F staining in
Rag1
2/2 mice (200X).
doi:10.1371/journal.pone.0040044.g002
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ALP, BMP2 and Runx2 had no significant differences in
expression. Hence, the resulting Rag1
2/2 primary bone cultures
showed a lower capacity for osteoblast differentiation and
expression of bone markers compared to WT mice.
Alizarin red staining of colonies (Fig. 4B) from primary
mesenchymal stromal cells of Rag1
2/2 and WT mice differen-
tiated to osteoblast colony-forming units showed a significant
decrease in mineralization at 20 days of culture in Rag1
2/2 mice
compared to WT suggesting an overall lack of mature osteoblast
activity in this T-cell deficient model. There were no differences
observed in the confluence or number of colonies between
Rag1
2/2 and WT mice cultures. Subsequent studies of Rag1
2/2
cultures (data not shown) of longer incubation periods greater
than 20 days followed by Alizarin red staining showed eventual
mineralization similar to that of WT cultures at 20 days
previously shown. Thus, mineralization did occur in the
Rag1
2/2 mice but in a delayed fashion.
Supporting in vivo calcein green fluorochrome labeling studies
(Fig. 4C) showed continued decreased mineralization and bone
formation in Rag1
2/2 mice even in the subsequent phases of
fracture healing at 14, 21 and 28 day time points compared to
WT. Calcein was administered at 2 and 9 days prior to harvest of
the limbs. With each fluorochrome label representing the injection
time points, the amount of bone formation during this 7 day
period was directly reflective of the distance measured between the
Figure 3. IL-17F promotes osteoblast maturation. (A) Treatment of MC3T3-E1 pre-osteoblast cell line cultures directly with pro-inflammatory
cytokine IL-17F showed increased bone marker gene expression of Col1, Col2, BSP and osteocalcin, whereas, anti-inflammatory cytokine TGFb
treatment inhibited osteoblast maturation and showed significant decreases in expression of the entire panel of bone markers analyzed. (B) Left:
Treatment of Rag1
2/2 mice primary mesenchymal stromal cell cultures directly with pro-inflammatory cytokine IL-17F showed increased bone marker
gene expression of Col1, Col2, and Runx2. Right: In contrast, treatment with anti-inflammatory cytokine TGFb inhibited WT mice primary
mesenchymal stromal cell maturation and showed significant decreases in expression of all the bone markers analyzed. (*p,0.05 and **p,0.01).
doi:10.1371/journal.pone.0040044.g003
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endosteum just outside the zone of the fracture callus on 3 different
sections were measured per group (n=3). The measured distances
between mineralization fronts were statistically significant at 14
(p,0.05) (image not shown), 21 (p,0.01) and 28 (p,0.01) days.
Thus, a consistent overall decrease in osteogenesis was observed in
the Rag1
2/2 mice throughout the different phases of fracture
healing. Unfractured limbs showed no significant differences in
bone formation.
The Fracture Callus from Rag1
2/2 Mice Shows Less
Healing than Observed in WT Mice
The differences in callus healing were assessed. Histologic data
indicated the persistence of a cartilage template and less
endochondral bone formation at 28 days in the Rag1
2/2 mice
compared to WT mice (Fig. 5A). More proteoglycan staining and
less bridging of the fracture gap with bone was apparent in the
Rag1
2/2 mice. This was further corroborated by longitudinal mCT
scan images of the fracture callus which were analyzed using
current stereologic/histomorphometric methods (Fig. 5B).
Qualitatively, the results indicated a larger, less healed bridging
fracture callus which quantitatively exhibited lower tissue mineral
density (TMD, p=0.004) and higher total callus volume (TV,
p=0.002) in Rag1
2/2 mice compared to WT calluses at 28 days
post fracture (Fig. 5C). The WT mice demonstrated more
advanced remodeling characteristics with a smaller, higher density
fracture callus. There were no differences seen (p.0.2) in bone
volume fraction (BV/TV), trabecular thickness (Tb.Th), trabecu-
lar number (Tb. N.) or trabecular separation (Tb.S.) between
groups at 28 days. At 35 days, there were no differences observed
Figure 4. Osteogenesis is reduced in Rag1
2/2 mice during fracture repair. (A) In vitro cultures of primary mesenchymal stromal cells
differentiated to osteoblast colony-forming units (CFU) showed lower gene expression levels of bone markers Col1, Col2 and BSP and osteocalcin in
Rag1
2/2 mice compared to WT. *p,0.05, **p,0.01 (n=10). (B) Alizarin red staining of osteoblast CFU showed significant decrease in mineralization
at 20 days of culture in Rag1
2/2 compared to WT. CFU-osteoblast was quantified by direct counting of all stained nodules positive to Alizarin Red
using light microscopy. (C) Digital fluorescent microscopy images of calcein green administered mice 2 and 9 days prior to harvest at 21 and 28 days
post fracture exhibited a smaller distance measured between mineralization fronts and hence, less bone formation in Rag1
2/2 compared to WT mice
(p,0.05). Unfractured limbs showed no significant differences in bone formation.
doi:10.1371/journal.pone.0040044.g004
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2/2 mice is delayed. (A) Safranin O staining of WT and Rag1
2/2 mice 28 days post fracture
showed persistence of a cartilage template with more proteoglycan staining (black arrows) and less bridging bone across the fracture gap in Rag1
2/2
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appears that bone healing eventually occurs in the Rag1
2/2 mice
but is delayed in comparison to WT mice.
Biomechanical testing showed higher ultimate torque and
torsional stiffness (p=0.002) in the Rag1
2/2 mice at 28 days
compared to WT (Fig. 5D). The elevated ultimate torque and
torsional stiffness between Rag1
2/2 and WT mice was no longer
significant at 35 days. Although an unexpected higher torsional
stiffness resulted from the biomechanical testing of Rag1
2/2 mice,
a presumption of better healing cannot be concluded based on this
data. The wider distribution of bone deposition around the
diaphyseal (neutral) axis, despite its reduced density, resulted in an
increased polar moment of inertia, leading to greater torsional
rigidity (p=0.002) (23).
Discussion
Here we found that a lack of T-cells delayed osteoblast
maturation and prolonged the proliferative phase of fracture
healing resulting in more immature osteoblasts and decreased
bone formation. Quantitative RNA expression studies of the
fracture callus and primary bone cultures confirmed the overall
decrease in mature osteoblasts correlated with the absence of T-
cells and its secreted factors in the early phases of fracture repair.
T-cells are selectively recruited in control human fractures during
the early phase of fracture repair [26] and T helper cells and
macrophages are disproportionately elevated in the fracture site
compared to what is seen systemically [4]. This indicates a
crucial role for T-cells in osteoblast regulation by subsequently
uncoupling the proliferative and remodeling phases of fracture
healing such that a lack of T-cells results in delayed and/or
impaired bone healing. This is commonly seen clinically in
immune deficient conditions such as those related to trauma,
autoimmune or malignancy disorders as well as malnutrition and
advanced age [14,27–31]. While the factors that determine
fracture repair in immune compromised patients are complex,
focusing on the T-cell mediated maturation of osteoblasts may
provide the critical link to understanding the actual fracture
repair mechanism. Our data defines a new role for T-cells in
regulating osteoblast differentiation, thus expanding on previous
information from investigations studying the role of T-cells in
bone of Rag1
2/2 [22] and dcT-cell deficient mice [32].
Based on the mCT analysis, the Rag1
2/2 mice demonstrated a
larger, lower density callus compared to WT at 28 days indicating
a more immature state of healing. While this wider but lower
density pattern of bone distribution led to an increased polar
moment of inertia (PMI) and greater torsional rigidity, this did not
indicate a more advanced state of bone healing. Torsional rigidity
is particularly relevant to heterogenous materials such as fracture
callus/healing bone. Torsional rigidity values calculated will not
be equal to the PMI values, but will show the same trends in that a
wider cross sectional area will yield both higher PMI and torsional
rigidity values. Torsional rigidity, however, is a more appropriate
metric to use as it more directly relates to experimentally measured
torsional stiffness incorporating both geometric and material
parameters vs. PMI which is representative of geometric
distribution alone. As such, torsional rigidity was used in this
study and has been utilized successfully in the recent biomechanics
literature with respect to assessing rodent long bones, including
fidelity of healed fractures in rat femora [23,33].
The cytokine expression data provided support for the concept
that an imbalance of pro- and anti-inflammatory cytokines may be
the underlying mechanism of osteogenesis. For this reason, we
directly treated osteoblast cells in culture with these cytokines to
observetheireffectsonmaturation.Indeed,IL-17Falone,promoted
increasedexpressionofosteoblastbonemarkers,highlightingforthe
first time, a key role for the pro-inflammatory cytokine IL-17F in
fracture healing. Thissuggests a model in fracture healing processes
whereby IL-17F, known to be secreted by the T-helper cell 17
(Th17) subset of T-cells, stimulates osteoblast maturation. More
importantly, the impaired osteoblast maturation and decreased
bone marker expression observed in Rag1
2/2 mice primary
mesenchymal stromal cells were able to be rescued with direct IL-
17F treatment further supporting its osteoinductive role. Immuno-
deficient Rag1
2/2 primary mesenchymal stromal cells demonstrat-
ed an impaired osteogenic potential compared to WT mice in vitro.
The lack of T-cells, including Th17, in the Rag1
2/2 mice is an
important difference as WT mice have Th17 cells in the bone
marrow which have the potential to be stimulated. Although the
Th17 cell stimulation was not fracture induced, the addition of
osteoblast differentiation media to the cultures after the initial
incubation period for cells to adhere did in fact influence bone
markerexpressioninWTcells.AsRag1
2/2micehaveanabsenceof
Th17 cells from the outset, the addition of osteoblast differentiation
media had little effect in inducing the markers for bone formation.
Thus, these results in part support the conclusions that T-cells are
important in osteoblast differentiation. However, mesenchymal
stromal cells do not express IL-17F and it was also not found to be
expressed in osteoblasts differentiated from primary mesenchymal
cells in vitro (data not shown). Hence, it is postulated that the
relevanceofafracturestimulusinvivoiskeytotheup-regulationand
expression of this essential pro-inflammatory cytokine to promote
bone formation and healing. Factors to which the cells are exposed
in the animal in vivo before they are harvested will influence cell
number or differentiation potential. This is illustrated by data
showing that even short term ovariectomy influences osteoblast
differentiation when cells are assayed in vitro [34].
Although IL-6 has modest effects on osteoblast differentiation
directly [35], upstream IL-6 increase early post fracture likely
promotes naı ¨ve CD4+ T-cells into Th17 cells stimulating pre-
osteoblast cell differentiation. Activated IL-6 (IL-6 bound to IL-6
receptor (IL-6R)) interacts with gp130, a signal transducing
subunit, to phosphorylate Janus kinase (Jak) to activate cytoplasmic
transcriptional factors in Th17 cells for the production of IL-17
[14,36,37]. Concomitantly, IL-6 has a dual role in the inhibition of
the regulatory T-cell (Treg) population [38,39] which prevents
Treg inhibition of osteoblast activity so as to further allow for
osteoblast activity to increase beyond its equilibrium state and
thus, allowing a net formation of bone to occur during fracture
healing (Fig. 6). This is supported by our qPCR expression data
from 3 and 7 day fracture callus RNA which revealed the
sustained down-regulation of IL-6 in Rag1
2/2 mice compared to
WT beyond the early phases of healing which resulted in less
mature osteoblasts and mineralization.
compared to WT mice. (B) mCT analysis confirmed the presence of a wider, lower density callus in Rag1
2/2 mice tibias at 28 days. (C) This was
reflected by increased total callus volume (TV) measurements (p=0.002) and decreased tissue mineral density (TMD) at 28 days in the Rag1
2/2
compared to WT mice (p=0.004). Torsional rigidity (TR) was significantly higher in Rag1
2/2 mice compared to WT (p=0.002). (D) Mechanical
assessment of the samples using torsional mechanical testing showed a significantly higher ultimate torque and torsional stiffness in the Rag1
2/2
mice at 28 days compared to WT (p=0.002).
doi:10.1371/journal.pone.0040044.g005
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impaired fracture healing is substantiated by other studies in the
literature. A lack of IL-6 expression in a mouse model was found
to have biomechanically weaker calluses during early fracture
healing [40]. Furthermore, TNFa, another pro-inflammatory
cytokine, was found to facilitate fracture repair, albeit through its
actions on the muscle-derived stromal cell population as opposed
to direct actions on the osteoblast population [1]. Another study
suggests that the pro-inflammatory cytokine IL-1b, accelerates
osteoblast differentiation and callus mineralization. However, the
authors ultimately did not find any net effects on fracture healing
with IL-1b deficiency alone, which they attributed to a multi-
factorial contribution by the other pro-inflammatory cytokines
[41].
It could be suggested that an alternative explanation to T-cell
modulation as the mechanism for osteoblast maturation would be
that the Rag1 gene itself is responsible for the maturation effects on
the osteoblast. It is unlikely, however, that expression of the Rag1
protein in the osteoblast is accountable for these findings. The
expression of the Rag1 gene is very tightly regulated and has no
significant activity beyond developing T-cells and B-cells. More-
over, given that the Rag1 protein is a recombinase and cleaves
DNA, its more ubiquitous expression would result in increased
tumorigenesis in bone which has not been reported [42].
A proposed mechanism derived from these findings is illustrated
in Figure 6. In this model of early fracture repair, the secretion of
IL-17F by Th17 T-cells is thought to enable osteoblast maturation
and activation, permitting bone synthesis to occur. IL-17F is a
more recently recognized addition to the family of pro-inflamma-
tory cytokines [14,38,43]. To date, IL-17A and F are known to
have roles in immunity augmenting the effects of IL-6 and TNFa,
with IL-17F known to be expressed in Th17, natural killer (NK)
and cdT-cells [38]. Here, these data suggest a novel link between
T-cells and osteoblast biology, with IL-17F being a key element. It
is possible that this may be the common regulatory point for bone
metabolism as there are studies in literature supporting its role in
promoting as well as inhibiting bone formation. One study [44]
found that IL-17A suppressed osteoclast differentiation when
applied at high concentrations in vitro, while another report [45]
found IL-17 to induce osteoclast formation. Similar to the
interaction between the osteoblast and osteoclast as mediated by
the RANK-RANKL pathway, whereby secretion of RANKL by
osteoblasts and its binding to the RANK receptor on the surface of
the osteoclast is required for activation of the osteoclast, IL-17 may
have effects on stimulating osteoblasts but at different concentra-
tions, producing either net osteoblast or osteoclast action through
its direct actions on the osteoblast. Furthermore, the action of
these molecules occurs in the context of a network of other
proteins and signaling pathways. It may be that a change in the
balance of activity between any of these pathways upstream of IL-
17 will produce either net bone formation or resorption.
A different balance of overall pathway activity and IL-17 levels
may also explain the differences between the cdT-cell deficient
model [32] our results in the Rag1
2/2 mice which exhibited
improved fracture healing. The Rag1
2/2 mouse model used in
our study would have produced a more global depletion of
lymphocytes, including Th17 cells and therefore, a different
cellular and cytokine fracture healing environment. Moreover,
cdT-cells have the ability to produce IL-10 and TGFb certainly
suggesting that they have the potential to inhibit osteoblast
differentiation [46]. While a recent study [22] also examined
fracture repair in Rag1
2/2 mice, our study focuses on the
mechanism of how the effectors of the adaptive immune system
alters mesenchymal progenitor differentiation via an imbalance
of pro- and anti-inflammatory cytokines. A decrease in pro-
inflammatory cytokines and an increase in anti-inflammatory
cytokines in the Rag1
2/2 mice, especially IL-10, reported in this
study, agree with our results. However, their conclusion of a
negative effect of lymphocytes on fracture healing was not
reproduced in our study. Nevertheless, the immune system and
its cellular activation and expression through cytokines as a
mechanism of fracture repair during osteoblast regulation are
Figure 6. Proposed mechanistic scheme of T-cell mediated osteoblast differentiation and maturation. Upstream IL-6 increase early post
fracture promotes naı ¨ve CD4+ T-cells to Th17 cells stimulating pre-osteoblast cell differentiation via IL-17F. Concomitantly, the Treg pathway is
suppressed, decreasing TGFb and IL-10 and inhibiting pre-osteoblast differentiation. The effect of IL-6 also has a direct role in the later stages of
osteoblast differentiation in fracture healing.
doi:10.1371/journal.pone.0040044.g006
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explore the specific signaling pathways involved in osteoblast
differentiation and maturation as modulated by T-cells.
In conclusion, our work has shown that a loss of expression of
Rag1
2/2, leading to a global depletion of lymphocytic activity
appears to be detrimental to the processes of fracture healing,
consistent with the assumption that T-cells are essential in fracture
healing. IL-17F not only can stimulate and promote osteoblast
maturation, but also has shown to directly rescue impaired healing
in vitro. In doing so, it may be the key mediator in regulating the
balance between a net osteoblast or osteoclast activity. As such,
future studies aimed at further elucidating the regulation of IL-17F
and its actions on mesenchymal progenitor cells may prove to be
pivotal in understanding of the interactions between the immune
system and bone healing.
Significance
This study provides a novel mechanism of interaction between
the immune system and bone healing, specifically on how T-cells
enable osteoblast maturation via IL-17F. This may provide future
molecular targets that may have clinical applications to improve
bone healing in those with nonunion or risks of impaired fracture
healing.
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